Is Noxopharm Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Noxopharm Ltd (NOX.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Noxopharm Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Noxopharm Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Noxopharm Ltd?

Muslim investors may consider investing in Noxopharm Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Noxopharm Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Noxopharm Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Noxopharm Ltd updated?

The Shariah compliance status of Noxopharm Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Noxopharm Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Noxopharm Ltd?

You can check the latest Shariah compliance status of Noxopharm Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NOX.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 29, 2025

Report Source: 2025 2nd Quarter Report

Noxopharm Ltd. Stock Analysis NOX.AX

Australia Health Care Nano Cap Report: Q2, 2025

Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales. The company went IPO on 2016-08-09. The company is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. The company utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.

Key Statistics of Noxopharm Ltd (NOX.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.06AUD0.06

Today's Open

AUD0.06

Volume

256.15K

P/E Ratio (TTM)

52 Week Range

AUD0.04AUD0.14

Market Cap

21.81M

Avg. Volume

74.74K

Dividend Yield

Financial Metrics & Statements of Noxopharm Ltd (NOX.AX)

FAQ's for Noxopharm Ltd (NOX.AX)

According to Musaffa’s Shariah screening methodology, Noxopharm Ltd (NOX.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.